Dr. Modest on Study of Surgical Intervention in CRC
Dominik P. Modest, MD
Published: Thursday, Jul 06, 2017
Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).
In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.
Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.
SELECTED LANGUAGE
Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).
In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.
Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.